At PDA/FDA Joint Regulatory Conference 2026, PCI Pharma's Bassler details how a QMS overhaul turned an FDA 483 into stronger quality culture.
News|Articles|July 13, 2021
FDA Clears Tevogen Bio’s IND Application for CTL COVID-19 Treatment
Author(s)Pharmaceutical Technology Editors
The IND for Tevogen Bio's TVGN-489, an allogeneic COVID-19-specific cytotoxic T lymphocyte, received rapid clearance from FDA.
Advertisement
FDA cleared Tevogen Bio’s investigational new drug application for its investigational COVID-19 treatment, TVGN-489, which is an allogeneic COVID-19-specific cytotoxic T lymphocyte (CTL), the company announced on July 12, 2021.
This clearance allows Tevogen Bio to begin clinical trials, which will evaluate the safety of TVGN-489 in high-risk COVID-19 patients and will also measure viral load and long-term immune response as secondary endpoints. In addition, the results of the patients receiving TVGN-489 will be compared to patients treated with the current standard of care. The previous
Programmed to detect targets from the entire viral genome, TVGN-489 is highly purified SARS-CoV-2 specific cytotoxic CD8+ T lymphocytes. The CTLs are anticipated to detect and kill virus-infected cells, which then allows the body to replace them with healthy, uninfected cells.
Source:
Advertisement
Related to this article
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Advertisement
Advertisement